Irritable bowel syndrome: a clinical review
- PMID: 25232249
- PMCID: PMC4161800
- DOI: 10.3748/wjg.v20.i34.12144
Irritable bowel syndrome: a clinical review
Abstract
Irritable bowel syndrome (IBS) remains a clinical challenge in the 21(st) century. It's the most commonly diagnosed gastrointestinal condition and also the most common reason for referral to gastroenterology clinics. Its can affect up to one in five people at some point in their lives, and has a significantly impact of life quality and health care utilization. The prevalence varies according to country and criteria used to define IBS. Various mechanisms and theories have been proposed about its etiology, but the biopsychosocial model is the most currently accepted for IBS. The complex of symptoms would be the result of the interaction between psychological, behavioral, psychosocial and environmental factors. The diagnosis of IBS is not confirmed by a specific test or structural abnormality. It is made using criteria based on clinical symptoms such as Rome criteria, unless the symptoms are thought to be atypical. Today the Rome Criteria III is the current gold-standard for the diagnoses of IBS. Secure positive evidence of IBS by means of specific disease marker is currently not possible and cannot be currently recommended for routine diagnosis. There is still no clinical evidence to recommend the use of biomarkers in blood to diagnose IBS. However, a number of different changes in IBS patients were demonstrated in recent years, some of which can be used in the future as a diagnostic support. IBS has no definitive treatment but could be controlled by non-pharmacologic management eliminating of some exacerbating factors such certain drugs, stressor conditions and changes in dietary habits.The traditional pharmacologic management of IBS has been symptom based and several drugs have been used. However, the cornerstone of its therapy is a solid patient physician relationship. This review will provide a summary of pathophysiology, diagnostic criteria and current and emerging therapies for IBS.
Keywords: Biopsychosocial model; Clinical review; Diagnostic; Irritable bowel syndrome; Pathogenesis; Treatment.
Similar articles
-
Irritable bowel syndrome - from etiopathogenesis to therapy.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Mar;162(1):1-9. doi: 10.5507/bp.2017.057. Epub 2018 Jan 18. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018. PMID: 29358788 Review.
-
Irritable Bowel Syndrome.Am J Nurs. 2017 Jun;117(6):48-55. doi: 10.1097/01.NAJ.0000520253.57459.01. Am J Nurs. 2017. PMID: 28541989 Free PMC article.
-
Management of irritable bowel syndrome.Intern Med. 2004 May;43(5):353-9. doi: 10.2169/internalmedicine.43.353. Intern Med. 2004. PMID: 15206545 Review.
-
Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine.World J Gastroenterol. 2014 Jun 14;20(22):6759-73. doi: 10.3748/wjg.v20.i22.6759. World J Gastroenterol. 2014. PMID: 24944467 Free PMC article. Review.
-
Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy.World J Gastroenterol. 2014 Jul 21;20(27):8807-20. doi: 10.3748/wjg.v20.i27.8807. World J Gastroenterol. 2014. PMID: 25083055 Free PMC article. Review.
Cited by
-
Irritable Bowel Syndrome and Risk of Parkinson's Disease in Finland: A Nationwide Registry-Based Cohort Study.J Parkinsons Dis. 2021;11(2):641-651. doi: 10.3233/JPD-202330. J Parkinsons Dis. 2021. PMID: 33646176 Free PMC article.
-
Depressive symptoms in patients with irritable bowel syndrome: a meta-analysis of comparative studies.Int J Biol Sci. 2018 Aug 15;14(11):1504-1512. doi: 10.7150/ijbs.25001. eCollection 2018. Int J Biol Sci. 2018. PMID: 30263003 Free PMC article.
-
An Open-Label Trial Study of Quality-of-Life Assessment in Irritable Bowel Syndrome and Their Treatment.Medicina (Kaunas). 2022 Jun 5;58(6):763. doi: 10.3390/medicina58060763. Medicina (Kaunas). 2022. PMID: 35744026 Free PMC article. Clinical Trial.
-
Low fermentable oligosaccharides, disaccharides, monosaccharides, and polypols diet and irritable bowel syndrome in Asia.JGH Open. 2018 Dec 28;3(2):173-178. doi: 10.1002/jgh3.12125. eCollection 2019 Apr. JGH Open. 2018. PMID: 31061894 Free PMC article. Review.
-
The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective.Therap Adv Gastroenterol. 2015 Sep;8(5):278-84. doi: 10.1177/1756283X15587866. Therap Adv Gastroenterol. 2015. PMID: 26327918 Free PMC article. Review.
References
-
- Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–721.e4. - PubMed
-
- Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet. 1987;1:963–965. - PubMed
-
- Locke GR. The epidemiology of functional gastrointestinal disorders in North America. Gastroenterol Clin North Am. 1996;25:1–19. - PubMed
-
- Cumming W. Electrogalvinism in a particular affliction of mucous membrane of the bowels. London Med Gaz. 1948;59:969–973.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources